PacBio to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit

PacBio (NASDAQ: PACB) announced today that it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.

MENLO PARK, Calif., Aug. 5, 2022 /PRNewswire/ --PacBio (NASDAQ: PACB) announced today that it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.

PacBio’s management is scheduled to participate in a fireside chat on Thursday, August 11 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time. The live webcast can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the presentation.

About PacBio

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB™ short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

Contacts

Investors:
Todd Friedman
650.521.8450
ir@pacb.com

Media:
Lizelda Lopez
pr@pacb.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pacbio-to-participate-in-the-ubs-genomics-2-0-and-medtech-innovations-summit-301600619.html

SOURCE Pacific Biosciences of California, Inc.


Company Codes: NASDAQ-NMS:PACB
MORE ON THIS TOPIC